Tuesday November 20, 12:00 pm Eastern Time
Press Release
SOURCE: OSI Pharmaceuticals, Inc.
OSI Pharmaceuticals to Host Conference Call and
Webcast From the Company's First Annual Research
Day
UNIONDALE, N.Y.--(BW HealthWire)--Nov. 20, 2001--OSI Pharmaceuticals, Inc. (Nasdaq:OSIP - news) today
announced that it will host a conference call and live webcast on Monday, November 26, at 12:00 p.m. EST from the
Company's First Annual Research Day. The webcast will be hosted by Colin Goddard, Ph.D., Chairman and Chief Executive
Officer of OSI Pharmaceuticals. OSI's management team is expected to discuss the Company's research and development
programs and capabilities, including OSI's leading anti-cancer compound Tarceva(TM) (OSI-774).
To access the event by conference call, please dial 800/997-8642 for domestic participants or 973/694-6836 for international
participants. To view the event via webcast, please connect to the Company's website at osip.com. In addition, a
replay of the presentation will be available from the same website for at least a week following the live presentation.
OSI Pharmaceuticals is a research driven biotechnology company primarily focused on the discovery, development and
commercialization of innovative products for the treatment of cancer and diabetes, and for selected opportunities arising from
the Company's extensive research and development programs. OSI utilizes a comprehensive array of drug discovery and
development technologies to target specific genes involved in human disease with novel small molecule drugs. The Company's
most advanced drug candidate Tarceva(TM), a small molecule inhibitor of the EGFR gene, is currently in Phase III clinical trials
for lung and pancreatic cancer.
This news release contains forward-looking statements. These statements are subject to known and unknown risks and
uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that
might cause such a difference include, among others, uncertainties related to the identification of lead compounds, the successful
pre-clinical development thereof, the completion of clinical trials, the FDA review process and other governmental regulation,
pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other
pharmaceutical companies, product pricing and third party reimbursement, and other factors described in OSI Pharmaceuticals'
filings with the Securities and Exchange Commission.
Contact:
OSI Pharmaceuticals, Inc.
Kathy Galante, 631/962-2000
kgalante@osip.com
or
Burns McClellan Representing OSI
Ethan Denkensohn (investors)
Justin Jackson (media)
Kathy Jones, Ph.D. (media)
212/213-0006 |
